High intensity exercise: Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.
Exercise guidance follows principles of self-efficacy and person-centeredness.
Study summary
Cardiovascular performance and overall fitness can be improved by high-intensity aerobic activity, and these benefits may be achievable by persons with rheumatic diseases. The investigators hypothesize that a 12-week high-intensity interval exercise program will provide substantial improvements in cardiovascular function, inflammation and symptoms affecting quality of life.
Eligibility
Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* Rheumatoid arthritis disease according to the American College of Rheumatology (ACR)/ The European Alliance of Associations for Rheumatology (EULAR) 1987/2010 criteria
* Disease duration \>1 year
* Age (range 20-60 years)
* Stable medication on anti- rheumatic drugs for \>3 months
* Low-to-moderate disease activity (\<5.1) according to the Disease activity score 28 (DAS28)
Exclusion Criteria:
* Cerebrovascular diseases
* Diabetes
* Severe hypertension
* Chronic obstructive pulmonary disease or other severe pulmonary diseases
* Other severe diseases that may be associated with adverse events or restrict participation in high-intensity exercise
* Arthroplasty of large joints
* Inability to manage Cardiopulmonary Exercise Testing (CPET)
* Pregnancy
* Already participating in regular aerobic or strength exercise at a high intensity level (\>1 hours/ week) during the last 6 months
* Inability to speak or read Swedish.
Primary outcome measure(s)
Cardiopulmonary function — 0 -12 weeks Maximum oxygen uptake (VO2ml/min/kg) (Higher value indicate better cardiorespiratory capacity)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
